西替利嗪辅助治疗对哮喘急性发作期患儿肺部通气功能及外周血巨噬细胞中Toll样受体水平的影响

刘娟; 赵宏芳

doi:10.7619/jcmp.202005015

西替利嗪辅助治疗对哮喘急性发作期患儿肺部通气功能及外周血巨噬细胞中Toll样受体水平的影响

刘娟,
赵宏芳^,

中国人民解放军空军军医大学第二附属医院儿科, 陕西西安, 710038

详细信息

通讯作者:
赵宏芳,E-mail:12481494@qq.com

中图分类号: R256.12
计量
- 文章访问数: 443
- HTML全文浏览量: 79
- PDF下载量: 16
出版历程
- 收稿日期: 2019-12-12
- 网络出版日期: 2020-08-26

Effect of cetirizine adjuvant therapy on pulmonary ventilation function and Toll-like receptor level in macrophages of peripheral blood in children with acute asthma attack

LIU Juan,
ZHAO Hongfang^,

Department of Pediatrics, The Second Affiliated Hospital of Air Force Military Medical University of People's Liberation Army, Xi'an, Shaanxi, 710038

摘要

摘要: 目的探讨西替利嗪辅助治疗对哮喘急性发作期患儿肺部通气功能及外周血巨噬细胞中Toll样受体(TLR)水平的影响。方法选择空军军医大学第二附属医院120例哮喘急性发作期患儿为研究对象,根据随机数字表法分为试验组(n=60)、对照组(n=60)。对照组采用布地奈德雾化吸入治疗,试验组在对照组基础上应用西替利嗪辅助治疗, 2组均治疗5 d。治疗5 d后,对比2组疗效、临床症状消失时间、不良反应; 观察治疗前、治疗5 d后肺部通气功能［第1秒呼气量(FEV₁)、用力肺活量(FVC)、呼气高峰流量(PEFR)］、外周血巨噬细胞中TLR1、TLR2、TLR4水平的变化。结果试验组治疗5 d后总有效率为91.67%, 高于对照组的75.00%(P<0.05); 试验组喘息、咳嗽、肺部哮鸣音消失时间短于对照组(P<0.05); 2组治疗5 d后FEV₁、FVC、PEFR水平较治疗前提高,且试验组高于对照组(P<0.05); 2组治疗5 d后外周血巨噬细胞中TLR1、TLR2水平较治疗前提高,且试验组高于对照组,TLR4水平较治疗前降低,且试验组低于对照组,2组比较差异均有统计学意义(P<0.05); 2组不良反应发生率相比,差异无统计学意义(P>0.05)。结论应用西替利嗪辅助治疗可增强哮喘急性发作期患儿的疗效,提升肺部通气功能,改善外周血巨噬细胞中TLR水平,促进患儿康复,且安全性较高。
- 西替利嗪 /
- 哮喘 /
- 肺部通气功能 /
- Toll样受体 /
- 症状消失时间
Abstract: Objective To explore the effect of cetirizine adjuvant therapy on pulmonary ventilation function and Toll-like receptor(TLR)level in macrophages of peripheral blood in children with acute asthma attack. Methods A total of 120 children with acute asthma attack in Second Affiliated Hospital of Air Force Military Medical University were randomly divided into experimental group(n=60)and control group(n=60). The control group was treated with budesonide aerosol inhalation and the experimental group was treated with cetirizine on the basis of the control group, the treatments of two groups were lasted for 5 days. The therapeutic effects, the disappearance time of clinical symptoms, adverse reactions after 5 days of treatment were observed. Lung ventilation function ［forced expiratory volume In one second(FEV₁), forced vital capacity(FVC), peak expiratory flow rate(PEFR)］ and the levels of TLR1, TLR2 and TLR4 in macrophages of peripheral blood before and after 5 days of treatment were also compared. Results The total effective rate of the experimental group was 91.67%, which was higher than 75.00% of the control group after 5 days of treatment(P< 0.05); the disappearance time of wheezing, coughing and lung wheezing in the experimental group- were shorter than that in the control group(P< 0.05); the levels of FEV₁, FVC and PEFR after 5 days of treatment in the two groups were higher than those before treatment, and the experimental group was higher than those in the control group(P< 0.05); the levels of TLR1 and TLR2 in blood macrophages were higher than those before treatment, and the level of TLR4 in the experimental group was lower than those in the control group, and the experimental group was better than that in the control group(P< 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P >0.05). Conclusion Cetirizine adjuvant therapy can enhance the curative effect, pulmonary ventilation function, improve the level of TLR in macrophages of peripheral blood, and promote the recovery of children with acute asthma attack, and it is safer.
- cetirizine /
- asthma /
- pulmonary ventilation function /
- Toll-like receptor /
- disappearance time of symptoms

HTML全文

参考文献(22)

Birzele L T, Depner M, Ege M J, et al. Environmental and mucosal microbiota and their role in childhood asthma[J]. Allergy, 2017, 72(1): 109-119.

Xu C J, Söderhäll C, Bustamante M, et al. DNA methylation in childhood asthma: an epigenome-wide meta-analysis[J]. Lancet Respir Med, 2018, 6(5): 379-388.

孙金峤. 特殊健康状态儿童预防接种专家共识之二: 支气管哮喘与预防接种[J]. 中国实用儿科杂志, 2018, 33(10): 738-739.

Ashley P J, Freemer M, Garbe P, et al. Coordinated federal actions are needed to reduce racial and ethnic disparities in childhood asthma[J]. J Public Health Manag Pract, 2017, 23(2): 207-209.

李娅宁, 王蕾, 耿磊, 等. 布地奈德联合不同药物雾化吸入治疗儿童哮喘疗效比较[J]. 中国医院药学杂志, 2017, 37(6): 533-537.

陈丙文, 陈斌斌, 石泽真. 孟鲁司特钠联合盐酸西替利嗪治疗咳嗽变异性哮喘儿童的临床观察[J]. 西北药学杂志, 2016, 31(3): 308-310.

张军, 李成城. Toll样受体在支气管哮喘发生中作用的研究进展[J]. 山东医药, 2018, 58(40): 95-98.

中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(9): 675-697.

雷春霞, 王石. 匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床观察[J]. 中国药房, 2016, 27(29): 4142-4144.

Deng R, Zhao F Y, Zhong X Y. T1 polymorphism in a disintegrin and metalloproteinase 33(ADAM33)gene may contribute to the risk of childhood asthma in Asians[J]. Inflamm Res, 2017, 66(5): 413-424.

刘树俊, 王婷婷, 曹世钰, 等. 中国儿童哮喘危险因素的Meta分析[J]. 中国当代儿科杂志, 2018, 20(3): 218-223.

Movin M, Garden F L, Protudjer J L, et al. Impact of childhood asthma on growth trajectories in early adolescence: Findings from the Childhood Asthma Prevention Study(CAPS)[J]. Respirology, 2017, 22(3): 460-465.

严炜. 顺尔宁联合布地奈德对支气管哮喘患儿炎症因子及气流受限的影响[J]. 临床与病理杂志, 2015, 35(6): 960-964.

吴玲玲. 布地奈德吸入联合孟鲁司特钠对小儿哮喘疗效及炎症因子的影响[J]. 中国妇幼保健, 2017, 32(1): 191-194.

李文, 宁君, 申长清, 等. 孟鲁司特及布地奈德对支气管哮喘儿童氧化应激的影响[J]. 临床肺科杂志, 2017, 22(2): 332-333.

王翠华. 雾化吸入糖皮质激素与H1受体阻滞剂治疗小儿哮喘相关指标的变化[J]. 菏泽医学专科学校学报, 2016, 28(2): 20-23.

顾剑华, 金晓群, 崔珍, 等. 丙酸氟替卡松气雾剂联合盐酸西替利嗪滴剂治疗儿童哮喘合并变应性鼻炎[J]. 广东医学, 2016, 37(23): 3607-3608.

李菲, 江桂松. 西替利嗪辅助治疗对哮喘患儿炎性因子及临床症状的影响[J]. 儿科药学杂志, 2016, 22(11): 10-13.

Magrone T, Simone M, Altamura M, et al. Characterization of the immune inflammatory profile in obese asthmatic children[J]. Endocr Metab Immune Disord Drug Targets, 2014, 14(3): 187-195.

陶聪, 李倩. 推拿联合自拟补肺定喘汤治疗哮喘慢性持续期患儿的疗效及对外周血巨噬细胞中Toll样受体表达的影响[J]. 现代中西医结合杂志, 2017, 26(20): 2206-2209.

陆嘉玮, 王谦, 赵祥安, 等. Toll样受体与支气管哮喘关系的研究进展[J]. 山东医药, 2017, 57(12): 104-107.

佟雪飞, 郭海军. 麻角定喘消痰汤对小儿哮喘发作外周血中Toll样受体表达的影响[J]. 中国生化药物杂志, 2015, 35(2): 130-132

, 136.